Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Longterm Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects With Moderate to Severe Chronic Low Back Pain.

Next Previous
Trial Profile

An Open Label, Longterm Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects With Moderate to Severe Chronic Low Back Pain.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 20 Aug 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Buprenorphine (Primary)
  • Indications Back pain
  • Focus Therapeutic Use
  • Sponsors BioDelivery Sciences International

Most Recent Events

  • 16 Apr 2012 Status changed from not yet recruiting to withdrawn as reported by ClinicalTrials.gov.
  • 16 Apr 2012 Actual initiation date (July 2012) added as reported by ClinicalTrials.gov.
  • 16 Apr 2012 Planned End Date changed from 1 Apr 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top